Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
MaxLinear announces third quarter 2025 financial results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results